College students, people living with AIDS, and community members held a “pool party” outside of Merck’s laboratories in Boston Friday, to speak out about the company’s hesitation to join the Medicines Patent Pool (MPP) – a two-year-old organization that works with drug companies to create licenses that allow generic drug companies to produce their patented […]
The National Institute of Allergy and Infectious Diseases (NIAID) is set to close out the HPTN 058 study, a Phase III clinical trial that started in 2007 and was tasked with evaluating whether or not administering opiate dependence medication, combined with drug and HIV risk-reduction counseling, can prevent HIV infection and death among opiate-dependent injection […]
HIV-infected patients who maintain undetectable levels of the virus are known as elite controllers – they have high or “normal” CD4 cell counts and behave just like HIV-negative people, said Mathias Lichterfeld of Harvard Medical School at a press conference Friday during the 49th Annual Meeting of the Infectious Diseases Society of America. Fending off […]
Researchers continue to unfold the curious link between HIV and GB Virus C (GBV-C). “Every study that shows persistent [GBV-C] infection over time has shown a survival benefit to HIV co-infected patients. How does this work? Why does this virus improve survival among people with HIV? Can we use it therapeutically?” Jack T Stapleton, MD, […]
Speaking out against a potential $16 million cut for military HIV research proposed in the Senate version of the Department of Defense Appropriations bill for fiscal year (FY) 2012, leaders of the Infectious Diseases Society of America (IDSA) and the HIV Medicine Association (HIVMA) sent a letter Thursday to the Secretary of the U.S. Army, John McHugh, making the case for sustaining the U.S. Military HIV Research Program (MHRP).
The following is a guest post by Jodi Jacobson, editor-in-chief of the blog RH Reality Check, where this post was originally published on October 5.
An article in Tuesday’s New York Times by Pam Belluck suggesting that injectable contraceptive use might double the risk of HIV transmission among women and their partners sent a wave of anxiety through the global public health community…
For every 1,000 patient-years of PEPFAR-supported HIV treatment provided, 228 fewer HIV patients die, 449 fewer children become orphans, 61 fewer sexual HIV transmissions occur and 26 fewer “vertical” transmissions (e.g. mother-to-child) occur. The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) Scientific Advisory Board heard the new PEPFAR ART Cost Model data from John Blanford, PhD, of the Centers for Disease Control and Prevention (CDC) in Washington, DC, on September 14…